MX383697B - Moduladores de moleculas peque?as de pantotenato cinasas - Google Patents

Moduladores de moleculas peque?as de pantotenato cinasas

Info

Publication number
MX383697B
MX383697B MX2018015170A MX2018015170A MX383697B MX 383697 B MX383697 B MX 383697B MX 2018015170 A MX2018015170 A MX 2018015170A MX 2018015170 A MX2018015170 A MX 2018015170A MX 383697 B MX383697 B MX 383697B
Authority
MX
Mexico
Prior art keywords
small molecule
molecule modulators
treatment
intended
pantothenate kinases
Prior art date
Application number
MX2018015170A
Other languages
English (en)
Spanish (es)
Other versions
MX2018015170A (es
Inventor
Charles O Rock
Chitra Subramanian
Jiuyu Liu
Lalit Kumar Sharma
Mi Kyung Yun
Richard E Lee
Suzanne Jackowski
Original Assignee
St Jude Childrens Res Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60783428&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX383697(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by St Jude Childrens Res Hospital Inc filed Critical St Jude Childrens Res Hospital Inc
Publication of MX2018015170A publication Critical patent/MX2018015170A/es
Publication of MX383697B publication Critical patent/MX383697B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MX2018015170A 2016-06-23 2017-06-23 Moduladores de moleculas peque?as de pantotenato cinasas MX383697B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662354012P 2016-06-23 2016-06-23
PCT/US2017/039037 WO2017223474A1 (en) 2016-06-23 2017-06-23 Small molecule modulators of pantothenate kinases

Publications (2)

Publication Number Publication Date
MX2018015170A MX2018015170A (es) 2019-07-04
MX383697B true MX383697B (es) 2025-03-14

Family

ID=60783428

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015170A MX383697B (es) 2016-06-23 2017-06-23 Moduladores de moleculas peque?as de pantotenato cinasas

Country Status (13)

Country Link
US (2) US10899734B2 (enExample)
EP (1) EP3474667A4 (enExample)
JP (1) JP7078555B2 (enExample)
KR (1) KR102459256B1 (enExample)
CN (1) CN109561680B (enExample)
AU (1) AU2017281907B2 (enExample)
DO (1) DOP2018000293A (enExample)
IL (1) IL263649B (enExample)
MX (1) MX383697B (enExample)
SA (1) SA518400696B1 (enExample)
SG (1) SG11201811023UA (enExample)
WO (1) WO2017223474A1 (enExample)
ZA (1) ZA201808099B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX383697B (es) 2016-06-23 2025-03-14 St Jude Childrens Res Hospital Inc Moduladores de moleculas peque?as de pantotenato cinasas
WO2019133632A1 (en) * 2017-12-27 2019-07-04 St. Jude Children's Research Hospital Methods of treating disorders associated with castor
MX2020006754A (es) * 2017-12-27 2021-01-29 St Jude Childrens Res Hospital Inc Moduladores de molécula pequeña de pantotenato-cinasas.
WO2020017569A1 (ja) * 2018-07-17 2020-01-23 日本ケミファ株式会社 Ｔ型カルシウムチャネル阻害剤
US12534451B2 (en) * 2019-03-27 2026-01-27 St. Jude Children's Research Hospital, Inc. Small molecule modulators of PanK
US20220226299A1 (en) * 2019-03-29 2022-07-21 Nippon Chemiphar Co., Ltd. Use of t-type calcium channel blocker for treating pruritus
JP2022081710A (ja) * 2019-03-29 2022-06-01 ユーティアイ リミテッド パートナーシップ 関節リウマチを治療するためのｔ型カルシウムチャネル阻害剤の使用
IL326597A (en) 2019-10-07 2026-04-01 Contineum Therapeutics Inc Muscarinic acetylcholine m1 receptor antagonists
US11752149B2 (en) 2019-12-02 2023-09-12 Pipeline Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
EP4262814A4 (en) * 2020-12-16 2025-02-26 St. Jude Children's Research Hospital, Inc. Methods of treating disorders associated with castor
JP2025528119A (ja) * 2022-08-08 2025-08-26 エイジャックス セラピューティクス， インコーポレイテッド Ｊａｋ２阻害剤としての複素環式アミド及び尿素化合物
WO2026012398A1 (zh) * 2024-07-09 2026-01-15 长春金赛药业有限责任公司 泛酸激酶pank小分子调节剂、药物组合物及其用途
CN119745886B (zh) * 2025-01-20 2026-04-14 中国药科大学 4-异丙苯基乙酰哌嗪在制备抗阿尔茨海默病药物中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4216212A (en) 1978-06-08 1980-08-05 The Procter & Gamble Company Pyrazolidine anti-inflammatory composition and methods of use
WO1998035957A1 (en) 1997-02-14 1998-08-20 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
MXPA03002263A (es) * 2000-09-14 2003-06-24 Schering Corp Antagonistas de receptor de neuropeptido y y5 de urea sustituidos.
US6894063B2 (en) * 2000-09-14 2005-05-17 Schering Corporation Substituted urea neuropeptide Y Y5 Receptor antagonists
US20050256130A1 (en) 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
DK1531822T3 (da) 2002-06-12 2009-12-07 Chemocentryx Inc 1-aryl-4-substituerede piperazin derivater til anvendelse som CCR1 antagonister til behandlingen af inflammation og immunforstyrrelser
US7262194B2 (en) 2002-07-26 2007-08-28 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
AR044688A1 (es) * 2003-06-12 2005-09-21 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor
US7759348B2 (en) 2003-07-30 2010-07-20 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
KR20060037410A (ko) * 2003-07-30 2006-05-03 제논 파마슈티칼스 인크. 피리다진 유도체 및 그의 치료제로서의 용도
WO2005113542A2 (en) 2004-05-20 2005-12-01 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
US7754724B2 (en) 2005-06-30 2010-07-13 Dow Agrosciences Llc N-substituted piperazines
US20080153811A1 (en) 2006-11-07 2008-06-26 Joseph Barbosa Methods of Treating Cognitive Impairment and Dementia
US8153633B2 (en) 2007-06-25 2012-04-10 Amgen Inc. Phthalazine compounds, compositions and methods of use
CA2692502C (en) 2007-07-05 2016-03-01 Array Biopharma Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
DE102007035333A1 (de) * 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
US8431608B2 (en) 2007-08-17 2013-04-30 Icagen Inc. Heterocycles as potassium channel modulators
US20100041663A1 (en) * 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
EP2414505B1 (en) 2009-04-02 2019-05-22 University of Florida Research Foundation, Inc. Engineering the pathway for succinate production
US8741611B2 (en) 2009-09-01 2014-06-03 Novozymes, Inc. Methods for improving malic acid production in filamentous fungi
US9187772B2 (en) 2010-09-01 2015-11-17 University Of Florida Research Foundation, Inc. L-malate production by metabolically engineered escherichia coli
HUE045810T2 (hu) 2010-09-27 2020-01-28 Exelixis Inc MET és VEGF kettõs inhibitorai kasztrációrezisztens prosztatarák és oszteoblasztos csontáttétek kezelésére
WO2013004642A1 (en) 2011-07-01 2013-01-10 Remynd Nv 1, 2, 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases
US20130303509A1 (en) * 2012-05-11 2013-11-14 Abbvie Inc. Nampt inhibitors
TW201444821A (zh) * 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
WO2016168619A1 (en) 2015-04-17 2016-10-20 Indiana University Research And Technology Corporation Hepatitis b viral assembly effectors
MX383697B (es) 2016-06-23 2025-03-14 St Jude Childrens Res Hospital Inc Moduladores de moleculas peque?as de pantotenato cinasas
MX2020006754A (es) 2017-12-27 2021-01-29 St Jude Childrens Res Hospital Inc Moduladores de molécula pequeña de pantotenato-cinasas.
WO2019133632A1 (en) 2017-12-27 2019-07-04 St. Jude Children's Research Hospital Methods of treating disorders associated with castor
WO2019133634A1 (en) 2017-12-27 2019-07-04 St. Jude Children's Research Hospital Small molecule modulators of pantothenate kinases
WO2020017569A1 (ja) 2018-07-17 2020-01-23 日本ケミファ株式会社 Ｔ型カルシウムチャネル阻害剤
EP4262814A4 (en) 2020-12-16 2025-02-26 St. Jude Children's Research Hospital, Inc. Methods of treating disorders associated with castor

Also Published As

Publication number Publication date
SA518400696B1 (ar) 2023-01-09
WO2017223474A1 (en) 2017-12-28
JP7078555B2 (ja) 2022-05-31
US12552765B2 (en) 2026-02-17
EP3474667A4 (en) 2019-11-27
AU2017281907B2 (en) 2021-10-21
RU2019101613A (ru) 2020-07-23
IL263649A (en) 2019-01-31
IL263649B (en) 2022-04-01
BR112018076441A2 (pt) 2019-04-09
KR102459256B1 (ko) 2022-10-25
NZ749147A (en) 2024-04-26
CA3025260A1 (en) 2017-12-28
US20190300499A1 (en) 2019-10-03
JP2019518764A (ja) 2019-07-04
DOP2018000293A (es) 2019-04-15
ZA201808099B (en) 2019-07-31
KR20190022620A (ko) 2019-03-06
CN109561680B (zh) 2021-07-13
US10899734B2 (en) 2021-01-26
RU2019101613A3 (enExample) 2020-12-03
AU2017281907A1 (en) 2019-01-03
MX2018015170A (es) 2019-07-04
CN109561680A (zh) 2019-04-02
US20210246113A1 (en) 2021-08-12
EP3474667A1 (en) 2019-05-01
SG11201811023UA (en) 2019-01-30

Similar Documents

Publication Publication Date Title
MX2020006754A (es) Moduladores de molécula pequeña de pantotenato-cinasas.
MX2018015170A (es) Moduladores de moleculas peque?as de pantotenato cinasas.
MX2016011898A (es) Composiciones de compuestos selenoorganicos y metodos de uso de los mismos.
PH12016500432B1 (en) Inhibitors of erk and methods of use
PH12015502615A1 (en) Chemical compounds
WO2017204445A3 (ko) Alk 단백질의 분해를 유도하는 약학적 조성물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
MX2017004896A (es) Uso de hexadeca-8, 15-dienal como producto quimico aromatico.
MX381290B (es) Formulaciones de peróxido y métodos y aplicaciones para utilizarlas.
WO2020198526A3 (en) Small molecule modulators of pank
JO3794B1 (ar) المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
BR112015022263A8 (pt) n-acil-n’-(piridin-2-il) uréias e análogos apresentando atividades anticâncer e antiproliferativas
PH12014502803A1 (en) Camsylate salt
MX2016004540A (es) Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
MX2017000524A (es) Compuestos novedosos de pirimidina sustituida.
WO2018104285A3 (de) Additive für flüssigkristallmischungen
PH12019500467A1 (en) Benzo-fused heterocyclic derivatives useful agonists of gpr120
GEAP201814266A (en) Pyrazines modulators of gpr6
IN2014DN09584A (enExample)
MX2016015959A (es) Derivados de carbamato los cuales son tanto inhibidores de la enzima fosfodiesterasa 4 (pde4) como antagonistas del receptor muscarinico m3.
MX2016010268A (es) Pirimidinimidazolaminas como modulares de actividad de cinasa.
MX368076B (es) Derivados de pirrol biciclicos utiles como agonistas de gpr120.
BR112017025901A2 (pt) composto, composição farmacêutica e uso de um composto
WO2014159251A3 (en) Inhibiting neurotransmitter reuptake
MX386660B (es) Una mezcla enriquecida con la estereoquimica r,r de 3',4'-di-o-acetil-cis-quelactona para el tratamiento de la diabetes mellitus.
HK1230177A1 (en) Trpa1 modulators